Last reviewed · How we verify
NCT05888909
Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
trial in Diabetic Nephropathy Type 2 in 2,000 participants. Currently enrolling.
1 November 2026
Quick facts
| Lead sponsor | Chinese PLA General Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 2,000 |
| Start date | 1 August 2022 |
| Primary completion | 1 November 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Conditions studied
- Diabetic Nephropathy Type 2 — all drugs for Diabetic Nephropathy Type 2 →
- Diabetic Kidney Disease — all drugs for Diabetic Kidney Disease →
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
Chinese PLA General Hospital
Who can join
18 and older, any sex, with Diabetic Nephropathy Type 2 or Diabetic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diabetes nephropathy (DN) is one of the most serious microvascular complications of diabetes, and also an important cause of death and disability of diabetes patients. There is no specific clinical staging of type 2 diabetes nephropathy at home and abroad, and there is no comprehensive study to comprehensively describe the occurrence and development of type 2 diabetes nephropathy through sensitive biomarkers, microvascular disease imaging and functional detection, digital markers and other multi-dimensional diagnosis and evaluation methods. Therefore, our research aims to establish a long-term follow-up queue for the whole cycle of diabetes nephropathy, develop multi-dimensional diagnostic and progress digital markers for diabetes nephropathy, develop a multimodal non-invasive diagnostic model and a new clinical staging/typing, and create a multi-dimensional accurate diagnosis and treatment system for type 2 diabetes nephropathy combining traditional Chinese and western medicine.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
COVID-19 epidemic investigation study of a follow-up cohort of patients with diabetic kidney disease.
Wang Q, Dong Z, Zhang W, Zheng Y, et al · · 2024 · PMID 39228893 · DOI 10.3389/fcimb.2024.1388260
Verify or expand the search:
- PubMed search for NCT05888909
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetic Nephropathy Type 2
Currently open trials in the same condition.
- NCT06586203 — Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes · NA · recruiting
- NCT06833541 — Research on Gut Microbiota and Metabolomics in Diabetic Kidney Disease · recruiting
- NCT04931537 — Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics. · recruiting
- NCT04573920 — Atrasentan in Patients With Proteinuric Glomerular Diseases · Phase 2 · active not recruiting
Other Chinese PLA General Hospital trials
Trials by the same sponsor.
- NCT07294755 — The Impact of Intrapleural Block on Postoperative Pain Caused by Drainage Tubes After Thoracoscopic Surgery · NA · not yet recruiting
- NCT07536607 — Predictive Role of Photon Counting Computed Tomography in Acute Coronary Syndrom Patients · not yet recruiting
- NCT07489157 — Real-Time End-Tidal Carbon Dioxide Monitoring for Early Warning of Hypoxemia in Painless Gastrointestinal Endoscopy · NA · not yet recruiting
- NCT07494981 — Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations · not yet recruiting
- NCT07496008 — Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05888909 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chinese PLA General Hospital
- Last refreshed: 5 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05888909.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing